Dovonex

Dovonex is a topical preparation containing calcipotriol, a synthetic vitamin D3 analogue used in the treatment of mild to moderate plaque psoriasis.

Calcipotriol works by slowing the excessive proliferation of skin cells that characterises psoriasis and by promoting normal differentiation of keratinocytes.

It also has a modest immunomodulatory effect, reducing local inflammation.

Plaque psoriasis involves an accelerated skin cell turnover, leading to thick, scaly, red patches.

By restoring a more normal rate of cell growth and shedding, Dovonex helps to flatten plaques, reduce scaling, and improve skin appearance.

It is available as a cream, ointment, and scalp solution, allowing treatment of psoriasis on various body sites including the scalp.

Dovonex is often used as a first-line topical treatment for psoriasis and may be combined with other therapies such as topical corticosteroids for enhanced efficacy.

It avoids many of the side effects associated with long-term steroid use, making it suitable for prolonged maintenance in many patients.

Apply a thin layer of Dovonex cream or ointment to the affected areas once or twice daily. For the scalp solution, apply to affected areas of the scalp twice daily. Rub in gently.

Wash your hands thoroughly after application unless you are treating the hands. Avoid applying to the face, as facial skin is more sensitive.

Results are usually visible after two to four weeks of regular use. Continue treatment as directed by your prescriber, even when the skin has improved, to maintain control and prevent relapse.

Adults should apply the cream or ointment to affected areas once or twice daily.

The maximum recommended amount is 100 g of cream or ointment per week, and no more than 60 ml of scalp solution per week. The total combined weekly dose should not exceed 5 mg of calcipotriol.

Children aged six to twelve should use no more than 50 g per week. The scalp solution and body preparation may be used concurrently, provided the weekly limits are respected.

Common side effects (up to 1 in 10 users) include local skin irritation, burning, stinging, itching, redness, and dryness at the application site. These effects are usually mild and transient.

Uncommon effects include a worsening of psoriasis, rash, and dermatitis at the treatment site.

Rarely, excessive use beyond recommended limits may raise blood calcium levels (hypercalcaemia), which can cause nausea, thirst, and fatigue. Adhere to the weekly dose limits to avoid this risk.

Do not exceed the recommended weekly dose, as over-application may lead to raised blood calcium levels. Avoid use on the face or in skin folds where absorption is increased.

Wash hands after application to prevent inadvertent transfer to the eyes or face. Dovonex may cause irritation if applied to sensitive or broken skin.

If combined with UV therapy, apply Dovonex after light treatment rather than before, as UV exposure may degrade calcipotriol.

Dovonex is contraindicated in patients with known disorders of calcium metabolism, including hypercalcaemia.

It should not be used by individuals with hypersensitivity to calcipotriol or any excipient in the product. It is not recommended for use in children under six years of age.